Literature DB >> 19275693

TNF-alpha in tuberculosis: a cytokine with a split personality.

Amanda Mootoo1, Elena Stylianou, Mauricio A Arias, Rajko Reljic.   

Abstract

TNF-alpha is an essential component of the innate defence mechanism of the host against pathogenic challenge. Unfortunately, it can also play a major role in the pathology of certain diseases, such as tuberculosis. This disease is a striking example of the role of TNF-alpha as a 'double-edged sword', because apart from its role in controlling the Mycobacterium tuberculosis infection, it can also cause severe tissue damage. TNF-alpha exhibits a very complex network of interactions and many of its activities are still not fully understood. This report aims to review the pivotal role of TNF-alpha in controlling the mycobacterial infection, with a particular emphasis on its influence on chemokine expression and cell movement during granuloma formation, and the issues surrounding the use of TNF-alpha inhibitors for therapeutic use in inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275693     DOI: 10.2174/187152809787582543

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  45 in total

1.  Association between CD53 genetic polymorphisms and tuberculosis cases.

Authors:  Hyun-Seok Jin; Jang-Eun Cho; Sangjung Park
Journal:  Genes Genomics       Date:  2018-11-30       Impact factor: 1.839

2.  Application of molecular, microbiological, and immunological tests for the diagnosis of bone and joint tuberculosis.

Authors:  Yinghua Tang; Lianli Yin; Shifu Tang; Hongyu Zhang; Jihui Lan
Journal:  J Clin Lab Anal       Date:  2017-05-22       Impact factor: 2.352

Review 3.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

4.  Serum and CSF cytokines and matrix metalloproteinases in spinal tuberculosis.

Authors:  Tushar Patil; Ravindra Kumar Garg; Amita Jain; Madhu Mati Goel; Hardeep Singh Malhotra; Rajesh Verma; Gyan Prakash Singh; Praveen Kumar Sharma
Journal:  Inflamm Res       Date:  2014-12-12       Impact factor: 4.575

5.  Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis.

Authors:  Wen-Lin Su; Wann-Cherng Perng; Ching-Hui Huang; Cheng-Yu Yang; Chin-Pyng Wu; Jenn-Han Chen
Journal:  Clin Vaccine Immunol       Date:  2009-12-09

Review 6.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

7.  Host-pathogen interaction and signaling molecule secretion are modified in the dpp3 knockout mutant of Candida lusitaniae.

Authors:  Ayman Sabra; Jean-Jacques Bessoule; Vessela Atanasova-Penichon; Thierry Noël; Karine Dementhon
Journal:  Infect Immun       Date:  2013-11-04       Impact factor: 3.441

8.  Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.

Authors:  Sang Kook Lee; Song Yee Kim; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Young Ae Kang
Journal:  Lung       Date:  2013-06-01       Impact factor: 2.584

9.  Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk.

Authors:  Joyce J B C van Beers; Jan G M C Damoiseaux
Journal:  Methods Mol Biol       Date:  2022

10.  Lactococcus lactis FNBPA+ (pValac:e6ag85a) Induces Cellular and Humoral Immune Responses After Oral Immunization of Mice.

Authors:  Camila Prósperi de Castro; Bianca Mendes Souza; Pamela Mancha-Agresti; Vanessa Bastos Pereira; Meritxell Zurita-Turk; Tatiane Melo Preisser; Vanessa Pecini da Cunha; Janete Soares Coelho Dos Santos; Sophie Yvette Leclercq; Vasco Azevedo; Anderson Miyoshi
Journal:  Front Microbiol       Date:  2021-05-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.